Review article: similarities and differences among delayed‐release proton‐pump inhibitor formulations

Summary Proton‐pump inhibitors are acid‐labile, and require an enteric coating to protect them from degradation in the stomach when given orally. However, this leads to delayed absorption and onset of action of the proton‐pump inhibitor. This article aims to review the similarities and differences between the various formulations of delayed release proton‐pump inhibitors. Delayed‐release omeprazole and delayed‐release lansoprazole have been suspended in sodium bicarbonate for tube administration; however, for omeprazole, absorption is further impaired and antisecretory effects are disappointing. Although such formulations may be more convenient for clinical use in certain patient groups, absorption of the proton‐pump inhibitor is still influenced by residual enteric coating. There are few differences among the currently available delayed‐release proton‐pump inhibitors with respect to their pharmacodynamic effects during chronic administration. There are minor formulation‐based pharmacokinetic differences among these agents, primarily reflected in their bioavailability following the first few doses. Differences in bioavailability may explain slight differences in the rate of onset of maximal antisecretory effect. However, minor pharmacodynamic and pharmacokinetic differences are not associated with meaningful differences in clinical outcomes.